- Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to quality care, in profitable shift from fee-for-service to value-based models.
- Its system helps decipher complex insurance contracts to maximize reimbursements.
- The software helps decipher complex insurance contracts to maximize reimbursements, integrating smoothly with major electronic health record systems to identify high-risk patients and care gaps.
- Adageis is continuously working with investors to expand its offerings for a growing list of small and independent practices.
Adageis, a forward-thinking healthcare technology company focused on value-based care solutions, is helping clinics and medical groups measure how their delivery of high-quality care translates into financial return. The company’s AI-driven platform enables providers to visualize revenue trends over time, identify where value-based incentives are being earned, and assess the impact of care improvements on the bottom line.
The ProActive Care platform, recently rebranded as a fintech AI solution, targets a long-standing challenge in healthcare: the complexity of insurance contracts. By clarifying how and when providers are rewarded for meeting care quality benchmarks, Adageis gives healthcare organizations a clearer picture of their performance and profitability.
For many smaller practices and clinics transitioning to value-based care, understanding these metrics can be difficult. Adageis offers tools to track performance in real time, linking patient outcomes with financial rewards. This transparency is especially important in today’s healthcare environment, where incentives increasingly hinge on quality, efficiency, and efficient population health management.
The ProActive Care Platform is central to the company’s offering, incorporating several proprietary components. One is the Value-Based Care Engine, designed to help organizations improve patient outcomes while meeting the standards required to unlock financial bonuses under value-based contracts.
Another core component is the Patented Risk Engine (“PRE”). It uses AI to detect high-risk patients and identify potential care gaps. This enables earlier interventions that can reduce costs over time while improving long-term outcomes. The company’s Proactive Efficiency system goes a step further, monitoring patient health continuously—not just during office visits—giving providers tools to act before conditions worsen.
Adageis also aims to reduce friction in the adoption of its technology. The platform includes a flexible API interface that integrates with widely used EHR systems such as Epic, Cerner, Allscripts, eClinicalWorks, and AthenaHealth. This compatibility allows providers to adopt the software without changing their core systems or workflows.
The company emphasizes its role not just as a software provider but as an advocate for healthcare organizations. Through its analytics and reporting tools, Adageis helps clients better understand what they are owed from insurers and where opportunities exist to improve their revenue position. The goal is to put clinics and medical groups in a stronger negotiating position while also improving care delivery.
Adageis continues to expand its offerings by working with investors interested in supporting small and independent practices. These smaller organizations often face greater financial and operational pressures when transitioning to new care models. By developing targeted solutions, Adageis aims to make value-based care accessible beyond large hospital systems or academic medical centers.
The company’s broader strategy includes influencing not only care delivery but also operational decisions. Its analytics can inform decisions around supply chain efficiency, practice location, and resource allocation, tying financial performance directly to operational choices.
As value-based care becomes more central to healthcare reimbursement, tools that quantify its financial impact will be increasingly important. Adageis positions itself as a key player in this transition, focusing on enabling providers to capture the revenue they’ve earned for delivering high-quality care.
For more information, visit the company’s website at www.Adageis.com.
NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
